*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
TADA3L tansfected 293T cell
Mouse, Rat, Bovine, Pig, Xenopus laevis, Chimpanzee, Rhesus Monkey(>80% identity)
0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
9.46 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant protein encompassing a sequence within the C-terminus region of human TADA3L. The exact sequence is proprietary.
Affinity purified by Protein A.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
transcriptional adaptor 3 , ADA3 , NGG1 , STAF54 , TADA3L , hADA3
Many DNA-binding transcriptional activator proteins enhance the initiation rate of RNA polymerase II-mediated gene transcription by interacting functionally with the general transcription machinery bound at the basal promoter. Adaptor proteins are usually required for this activation, possibly to acetylate and destabilize nucleosomes, thereby relieving chromatin constraints at the promoter. The protein encoded by this gene is a transcriptional activator adaptor and has been found to be part of the PCAF histone acetylase complex. In addition, it associates with the tumor suppressor protein p53 and is required for full activity of p53 and p53-mediated apoptosis. At least four alternatively spliced variants have been found for this gene, but the full-length nature of some variants has not been determined. [provided by RefSeq]